Amgen Inc. and Allergan PLC's two biosimilars Mvasi (bevacizumab-awwb) and Kanjinti (trastuzumab-anns) are the first to test the US commercial market for cancer biosimilars – and having won at least one important insurance coverage decision from [UnitedHealthCare], the launches appear off to a steady start.
UnitedHealthCare announced it will cover the two biosimilars in a preferred position to Roche's reference drugs Avastin and Herceptin beginning on 1 October for new patient starts. For existing patients, Avastin and Herceptin will be allowed. Amgen launched the biosimilars in July at-risk as the first biosimilar versions of Roche's Avastin and Herceptin, respectively
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?